2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$76.36+$0.25 (+0.33%)
Price as of Jul 14, 2026 4:29 AM EDT- $9.0BMarket Cap
- 32.02%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$76.36+$0.25 (+0.33%)
HALO | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $76.11 | ||
Change | -$0.09 (-0.12%) | ||
Open | $75.94 | ||
High | $76.99 | ||
Low | $74.52 | ||
Previous Close | $76.20 | ||
Volume | 1,822,560 | ||
30-Day Average Volume | 2,037,358 | ||
1-Week Change | -5.78% | ||
1-Month Change | 9.51% | ||
1-Year Change | 32.02% | ||
3-Year Change | 94.11% | ||
5-Year Change | 69.51% | ||
Fundamentals | |||
Shares Outstanding | 118.6M | ||
Total Assets | $2.7B | ||
Market Cap | $9.0B | ||
Enterprise Value | $10.9B | ||
Period: QTR TTM FY | |||
Revenue | $240.7M | ||
Net Income | $150.0M | ||
Free Cash Flow | $176.3M | ||
EBIT | $180.7M | ||
EBITDA | $210.2M | ||
Net Working Capital | $639.8M | ||
EPS | $1.22 | ||
Enterprise Value/EBITDA | 52 | ||
Enterprise Value/Revenue | 45 | ||
P/B | 41 | ||
P/E | 62 | ||
PEG | 0 | ||
Price/Free Cash Flow | 51 | ||
Price/Operating Cash Flow | 50 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue